https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/659987/thin-evidence-underpins-congress-probe-of-china-trial-consenthttps://www.biocentury.com/article/659987/thin-evidence-underpins-congress-probe-of-china-trial-consent?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTHIN EVIDENCE UNDERPINS CONGRESS' PROBE OF CHINA TRIAL CONSENTHouse committee letters echo Capitol Hill memo, cite ethics concerns that are not unique to ChinaTue, 30 Jun 2026 16:05:07 -0700https://www.biocentury.com/article/659981/abivax-completes-round-trip-after-uc-malignancy-scarehttps://www.biocentury.com/article/659981/abivax-completes-round-trip-after-uc-malignancy-scare?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTABIVAX COMPLETES ROUND TRIP AFTER UC MALIGNANCY SCAREBioCentury’s Clinical Report June 24 – 30Tue, 30 Jun 2026 16:01:20 -0700https://www.biocentury.com/article/659925/fda-s-july-calendar-features-at-least-10-decision-dateshttps://www.biocentury.com/article/659925/fda-s-july-calendar-features-at-least-10-decision-dates?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEFDA’S JULY CALENDAR FEATURES AT LEAST 10 DECISION DATESApplications include a cell therapy delayed from AprilTue, 30 Jun 2026 15:16:13 -0700https://www.biocentury.com/article/659982/wuxi-apptec-seeks-injunction-removing-chinese-military-designationhttps://www.biocentury.com/article/659982/wuxi-apptec-seeks-injunction-removing-chinese-military-designation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWUXI APPTEC SEEKS INJUNCTION REMOVING ‘CHINESE MILITARY’ DESIGNATIONMotion cites recent Anthropic win as precedent, reiterates lack of control by or affiliation with Chinese government, militaryTue, 30 Jun 2026 13:46:33 -0700https://www.biocentury.com/article/659971/chugai-brings-platform-first-partnering-to-south-san-franciscohttps://www.biocentury.com/article/659971/chugai-brings-platform-first-partnering-to-south-san-francisco?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSCHUGAI BRINGS PLATFORM-FIRST PARTNERING TO SOUTH SAN FRANCISCOJapanese pharma aims to turn U.S. academic visibility into early collaborations built around its antibody and macrocyclic peptide technologiesTue, 30 Jun 2026 13:28:52 -0700https://www.biocentury.com/article/659947/vc-backed-kartos-sells-to-ipsen-in-backloaded-agreement-deals-reporthttps://www.biocentury.com/article/659947/vc-backed-kartos-sells-to-ipsen-in-backloaded-agreement-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSVC-BACKED KARTOS SELLS TO IPSEN IN BACKLOADED AGREEMENT: DEALS REPORTPlus: Novartis, Antares in discovery deal; Zymeworks buys Theravance; Germany-based Merck acquires tools company Bio-Techne; and moreMon, 29 Jun 2026 15:05:06 -0700https://www.biocentury.com/article/659952/mrgprx2-fails-key-csu-test-as-evommune-drops-urticaria-programhttps://www.biocentury.com/article/659952/mrgprx2-fails-key-csu-test-as-evommune-drops-urticaria-program?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMRGPRX2 FAILS KEY CSU TEST AS EVOMMUNE DROPS URTICARIA PROGRAMPhase IIb miss with EVO756 clouds prospects for blocking a single mast-cell activation pathway in chronic hivesMon, 29 Jun 2026 14:51:53 -0700https://www.biocentury.com/article/659955/klomp-consolidates-power-at-hhs-oversees-fda-leadership-shufflehttps://www.biocentury.com/article/659955/klomp-consolidates-power-at-hhs-oversees-fda-leadership-shuffle?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWKLOMP CONSOLIDATES POWER AT HHS, OVERSEES FDA LEADERSHIP SHUFFLETrump has selected a pragmatic dealmaker to take charge of public health, signaling a shift from ideologyMon, 29 Jun 2026 14:42:19 -0700https://www.biocentury.com/article/659958/parkinson-s-deep-dive-fda-trial-reforms-a-biocentury-podcasthttps://www.biocentury.com/article/659958/parkinson-s-deep-dive-fda-trial-reforms-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONPARKINSON’S DEEP DIVE & FDA TRIAL REFORMS — A BIOCENTURY PODCASTPlus AZ’s obesity build-out and FDA’s reversion to the mean on regulatory decisionsMon, 29 Jun 2026 13:29:26 -0700https://www.biocentury.com/article/659801/building-out-in-obesityhttps://www.biocentury.com/article/659801/building-out-in-obesity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTBUILDING OUT IN OBESITYAstraZeneca is building an obesity portfolio it hopes can compete beyond the GLP-1 incumbentsMon, 29 Jun 2026 12:35:37 -0700https://www.biocentury.com/article/659787/immunic-tests-nurr1-to-push-beyond-ms-s-inflammation-ceilinghttps://www.biocentury.com/article/659787/immunic-tests-nurr1-to-push-beyond-ms-s-inflammation-ceiling?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTIMMUNIC TESTS NURR1 TO PUSH BEYOND MS’S INFLAMMATION CEILING Phase III candidate vidofludimus calcium will show whether pairing DHODH inhibition with direct neuroprotective effects can slow MS progressionFri, 26 Jun 2026 18:00:04 -0700https://www.biocentury.com/article/659932/house-committee-to-vote-on-china-investment-and-in-licensing-restrictionshttps://www.biocentury.com/article/659932/house-committee-to-vote-on-china-investment-and-in-licensing-restrictions?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWHOUSE COMMITTEE TO VOTE ON CHINA INVESTMENT AND IN-LICENSING RESTRICTIONSRules Committee will consider proposals to add BINSA, research restrictions, and domestic biomanufacturing support to the NDAAFri, 26 Jun 2026 16:21:18 -0700https://www.biocentury.com/article/659927/definium-s-805m-offering-leads-follow-on-quartet-public-equity-reporthttps://www.biocentury.com/article/659927/definium-s-805m-offering-leads-follow-on-quartet-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEDEFINIUM’S $805M OFFERING LEADS FOLLOW-ON QUARTET: PUBLIC EQUITY REPORTPlus: uniQure, MoonLake and Taysha round out group raising nearly $1.5B combinedFri, 26 Jun 2026 16:06:28 -0700https://www.biocentury.com/article/659929/chmp-joins-fda-in-challenging-tavneos-approval-basishttps://www.biocentury.com/article/659929/chmp-joins-fda-in-challenging-tavneos-approval-basis?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONCHMP JOINS FDA IN CHALLENGING TAVNEOS’ APPROVAL BASISRecommendation to revoke EU authorization follows FDA withdrawal proposal, with both agencies citing data integrity concernsFri, 26 Jun 2026 15:49:15 -0700https://www.biocentury.com/article/659934/upcoming-fda-adcomms-will-test-post-makary-independencehttps://www.biocentury.com/article/659934/upcoming-fda-adcomms-will-test-post-makary-independence?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONUPCOMING FDA ADCOMMS WILL TEST POST-MAKARY INDEPENDENCE Replimune and Capricor meetings revisit Prasad-era controversies, while peptide review will test MAHA’s influence over FDAFri, 26 Jun 2026 14:39:34 -0700https://www.biocentury.com/article/659905/rq-bio-raises-115m-to-advance-long-acting-antibody-prophylaxis-for-flu-venture-reporthttps://www.biocentury.com/article/659905/rq-bio-raises-115m-to-advance-long-acting-antibody-prophylaxis-for-flu-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCERQ BIO RAISES $115M TO ADVANCE LONG-ACTING ANTIBODY PROPHYLAXIS FOR FLU: VENTURE REPORTPlus: Patient Square backs Osanni’s hub-and-spoke model; Nura moves ahead in neurodegeneration; and a handful of NewCos draw cashThu, 25 Jun 2026 14:41:40 -0700https://www.biocentury.com/article/659912/hengrui-rising-frank-jiang-on-building-a-global-biotechhttps://www.biocentury.com/article/659912/hengrui-rising-frank-jiang-on-building-a-global-biotech?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSHENGRUI RISING: FRANK JIANG ON BUILDING A GLOBAL BIOTECHBehind the deals and R&D of China’s top biopharma Thu, 25 Jun 2026 12:54:14 -0700https://www.biocentury.com/article/659914/tryngolza-expansion-gives-ionis-its-first-prevalent-market-testhttps://www.biocentury.com/article/659914/tryngolza-expansion-gives-ionis-its-first-prevalent-market-test?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONTRYNGOLZA EXPANSION GIVES IONIS ITS FIRST PREVALENT-MARKET TESTFDA approval moves Tryngolza from rare FCS into severe hypertriglyceridemia, giving Ionis its first shot at a broad cardiometabolic marketThu, 25 Jun 2026 12:35:58 -0700https://www.biocentury.com/article/659850/newco-boom-picks-up-pace-in-1h26https://www.biocentury.com/article/659850/newco-boom-picks-up-pace-in-1h26?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTENEWCO BOOM PICKS UP PACE IN 1H26Halfway through the year, at least 13 West-based companies have launched with Asian assets, nearly matching 2025’s full-year totalThu, 25 Jun 2026 08:54:40 -0700https://www.biocentury.com/article/659890/where-trialblazer-puts-fda-ahead-and-where-china-still-leadshttps://www.biocentury.com/article/659890/where-trialblazer-puts-fda-ahead-and-where-china-still-leads?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONWHERE TRIALBLAZER PUTS FDA AHEAD — AND WHERE CHINA STILL LEADSThe U.S. roadmap could speed trial starts, but China retains advantages in parallel review, faster IND pathways, and regulatory flexibilityWed, 24 Jun 2026 15:50:38 -0700https://www.biocentury.com/article/659888/tracking-fda-s-trialblazer-reformshttps://www.biocentury.com/article/659888/tracking-fda-s-trialblazer-reforms?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONTRACKING FDA’S TRIALBLAZER REFORMSSome actions are already complete, but the biggest changes to IND review, IRBs and trial enrollment remain aheadWed, 24 Jun 2026 15:25:03 -0700https://www.biocentury.com/article/659882/planned-reforms-could-narrow-but-not-close-u-s-china-trial-start-gaphttps://www.biocentury.com/article/659882/planned-reforms-could-narrow-but-not-close-u-s-china-trial-start-gap?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONPLANNED REFORMS COULD NARROW, BUT NOT CLOSE, U.S.-CHINA TRIAL START GAPOperation TrialBlazer combines short-term incremental reforms with attempts at transformational changeWed, 24 Jun 2026 15:10:06 -0700https://www.biocentury.com/article/659691/expedition-medicines-generative-covalent-chemistry-to-unlock-difficult-targets-at-scalehttps://www.biocentury.com/article/659691/expedition-medicines-generative-covalent-chemistry-to-unlock-difficult-targets-at-scale?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEEXPEDITION MEDICINES: GENERATIVE COVALENT CHEMISTRY TO UNLOCK DIFFICULT TARGETS AT SCALEFlagship’s Expedition is training AI on proteome-wide reactivity data and quantum chemistry to design covalent small moleculesWed, 24 Jun 2026 14:47:26 -0700https://www.biocentury.com/article/659712/ebola-outbreak-exposes-treatment-gaphttps://www.biocentury.com/article/659712/ebola-outbreak-exposes-treatment-gap?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTEBOLA OUTBREAK EXPOSES TREATMENT GAPWHO prioritizes Zaire-tested mAbs, antivirals as academic labs seek path for strain-specific, pan-Ebolavirus therapiesTue, 23 Jun 2026 22:35:30 -0700https://www.biocentury.com/article/659715/retinitis-pigmentosa-emerges-as-next-genetic-medicine-test-bedhttps://www.biocentury.com/article/659715/retinitis-pigmentosa-emerges-as-next-genetic-medicine-test-bed?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTRETINITIS PIGMENTOSA EMERGES AS NEXT GENETIC MEDICINE TEST BEDAs therapies for one form of retinitis pigmentosa near the market, new technologies put subtype-agnostic therapies in reachTue, 23 Jun 2026 18:07:06 -0700https://www.biocentury.com/article/659878/r-d-leadership-changes-for-sanofi-revolutionhttps://www.biocentury.com/article/659878/r-d-leadership-changes-for-sanofi-revolution?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSR&D LEADERSHIP CHANGES FOR SANOFI, REVOLUTIONPlus: Nate Chang joins Wells Fargo’s investment banking team, moves at Pfizer, Moderna and moreTue, 23 Jun 2026 17:30:06 -0700https://www.biocentury.com/article/659875/is-legacy-tech-or-the-target-to-blame-in-pfizer-s-phase-iii-lung-cancer-misshttps://www.biocentury.com/article/659875/is-legacy-tech-or-the-target-to-blame-in-pfizer-s-phase-iii-lung-cancer-miss?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTIS LEGACY TECH OR THE TARGET TO BLAME IN PFIZER’S PHASE III LUNG CANCER MISS?BioCentury’s clinical report June 16–23Tue, 23 Jun 2026 17:20:04 -0700https://www.biocentury.com/article/659871/newco-serapha-taking-path-to-nasdaq-via-merger-with-boundless-deals-reporthttps://www.biocentury.com/article/659871/newco-serapha-taking-path-to-nasdaq-via-merger-with-boundless-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSNEWCO SERAPHA TAKING PATH TO NASDAQ VIA MERGER WITH BOUNDLESS: DEALS REPORTPlus: Sangamo enters bankruptcy, finds two bidders for assets; and moreTue, 23 Jun 2026 17:07:58 -0700https://www.biocentury.com/article/659876/ftc-pushes-back-against-court-s-antitrust-standard-in-j-j-biosimilar-casehttps://www.biocentury.com/article/659876/ftc-pushes-back-against-court-s-antitrust-standard-in-j-j-biosimilar-case?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWFTC PUSHES BACK AGAINST COURT’S ANTITRUST STANDARD IN J&J BIOSIMILAR CASEFTC brief argues J&J's acquisition of Momenta's patents broke antitrust law if it harmed competition — regardless of what J&J intendedTue, 23 Jun 2026 15:17:06 -0700https://www.biocentury.com/article/659864/abbvie-m-a-fda-reversals-a-car-t-first-a-biocentury-podcasthttps://www.biocentury.com/article/659864/abbvie-m-a-fda-reversals-a-car-t-first-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSABBVIE M&A, FDA REVERSALS, A CAR T FIRST — A BIOCENTURY PODCASTAbbVie’s $10.9B Apogee takeout, FDA’s post-Makary course corrections, and CARsgen’s solid tumor CAR T approvalMon, 22 Jun 2026 17:11:17 -0700https://www.biocentury.com/article/659848/abbvie-seeks-further-extension-to-immunology-franchise-via-10-9b-apogee-dealhttps://www.biocentury.com/article/659848/abbvie-seeks-further-extension-to-immunology-franchise-via-10-9b-apogee-deal?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSABBVIE SEEKS FURTHER EXTENSION TO IMMUNOLOGY FRANCHISE VIA $10.9B APOGEE DEALTakeout adds long-acting atopic dermatitis therapy, headed into Phase III, that could compete with Dupixent and EbglyssMon, 22 Jun 2026 16:44:23 -0700https://www.biocentury.com/article/659859/satri-cel-ushers-car-t-into-solid-tumors-but-not-on-the-modality-s-usual-termshttps://www.biocentury.com/article/659859/satri-cel-ushers-car-t-into-solid-tumors-but-not-on-the-modality-s-usual-terms?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTSATRI-CEL USHERS CAR T INTO SOLID TUMORS, BUT NOT ON THE MODALITY’S USUAL TERMSChina’s approval of CARsgen’s satri-cel gives CAR T its first solid tumor foothold, and a new calculus for its cost, complexity, and safetyMon, 22 Jun 2026 16:41:55 -0700https://www.biocentury.com/article/659857/regenxbio-s-gene-therapy-latest-example-of-fda-s-reversion-to-the-meanhttps://www.biocentury.com/article/659857/regenxbio-s-gene-therapy-latest-example-of-fda-s-reversion-to-the-mean?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONREGENXBIO’S GENE THERAPY LATEST EXAMPLE OF FDA’S REVERSION TO THE MEANAt least 11 products derailed under Makary, Prasad, Høeg are back on track as if they hadn't happenedMon, 22 Jun 2026 16:31:08 -0700https://www.biocentury.com/article/659817/human-neural-models-get-closer-to-cns-diseasehttps://www.biocentury.com/article/659817/human-neural-models-get-closer-to-cns-disease?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONHUMAN NEURAL MODELS GET CLOSER TO CNS DISEASEBioCentury’s Distillery highlights organoids, assembloids, and engineered neurons modeling CNS disease across circuits, time, and vulnerable cellsMon, 22 Jun 2026 13:30:32 -0700https://www.biocentury.com/article/659783/front-row-with-biocentury-cancer-s-next-wavehttps://www.biocentury.com/article/659783/front-row-with-biocentury-cancer-s-next-wave?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTFRONT ROW WITH BIOCENTURY: CANCER’S NEXT WAVETranslational science driving clinical innovation in cancerThu, 18 Jun 2026 17:28:02 -0700https://www.biocentury.com/article/659823/kardigan-s-400m-ipo-is-latest-followed-by-aftermarket-gains-finance-reporthttps://www.biocentury.com/article/659823/kardigan-s-400m-ipo-is-latest-followed-by-aftermarket-gains-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEKARDIGAN’S $400M IPO IS LATEST FOLLOWED BY AFTERMARKET GAINS: FINANCE REPORTPlus: series A rounds for MultiValent and Vedana, and moreThu, 18 Jun 2026 17:23:58 -0700https://www.biocentury.com/article/659836/continuing-signs-of-political-involvement-at-fdahttps://www.biocentury.com/article/659836/continuing-signs-of-political-involvement-at-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWCONTINUING SIGNS OF POLITICAL INVOLVEMENT AT FDAPost-Makary meetings with Replimune, Amgen and others raise questions about political access in regulatory disputesThu, 18 Jun 2026 16:59:54 -0700https://www.biocentury.com/article/659819/europe-s-narrow-path-between-the-u-s-and-china-in-biotechhttps://www.biocentury.com/article/659819/europe-s-narrow-path-between-the-u-s-and-china-in-biotech?utm_source=bc_rss&utm_medium=rssBIOCENTURY | GUEST COMMENTARYEUROPE’S NARROW PATH BETWEEN THE U.S. AND CHINA IN BIOTECHEurope has an opening to become biotech’s third pole, but only if it engages China while anchoring IP, manufacturing, and development at homeThu, 18 Jun 2026 14:59:18 -0700https://www.biocentury.com/article/659785/vedana-taking-a-two-pathway-shot-at-migrainehttps://www.biocentury.com/article/659785/vedana-taking-a-two-pathway-shot-at-migraine?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEVEDANA: TAKING A TWO-PATHWAY SHOT AT MIGRAINESeattle-based biotech emerges with $46M series A to advance antibodies for migraineThu, 18 Jun 2026 13:25:58 -0700https://www.biocentury.com/article/659803/with-123m-to-invest-kos-aims-to-build-bridge-to-greek-biotech-ecosystemhttps://www.biocentury.com/article/659803/with-123m-to-invest-kos-aims-to-build-bridge-to-greek-biotech-ecosystem?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEWITH $123M TO INVEST, KOS AIMS TO BUILD BRIDGE TO GREEK BIOTECH ECOSYSTEMSimeonidis, Tzoukas aim to draw on ‘diaspora’ of talent to build connections to Southeastern European nationThu, 18 Jun 2026 13:23:55 -0700https://www.biocentury.com/article/659807/this-ai-moment-two-steps-forward-and-one-step-back-chris-arendthttps://www.biocentury.com/article/659807/this-ai-moment-two-steps-forward-and-one-step-back-chris-arendt?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONTHIS AI MOMENT: TWO STEPS FORWARD AND ONE STEP BACK – CHRIS ARENDTTakeda CSO in conversation at BioCentury Grand Rounds U.S. on successes and challenges of bringing AI into a 250-year-old pharma companyWed, 17 Jun 2026 18:10:02 -0700https://www.biocentury.com/article/659813/uniqure-reversal-puts-natural-history-controls-back-in-play-for-rare-neurohttps://www.biocentury.com/article/659813/uniqure-reversal-puts-natural-history-controls-back-in-play-for-rare-neuro?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTUNIQURE REVERSAL PUTS NATURAL-HISTORY CONTROLS BACK IN PLAY FOR RARE NEUROFDA’s U-turn on AMT-130 gives Huntington’s and other rare disease sponsors a counterweight to CBER’s earlier rejection of external-control dataWed, 17 Jun 2026 18:07:48 -0700https://www.biocentury.com/article/659808/senate-bill-seeks-to-enhance-dod-s-ability-to-sanction-chinese-companieshttps://www.biocentury.com/article/659808/senate-bill-seeks-to-enhance-dod-s-ability-to-sanction-chinese-companies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWSENATE BILL SEEKS TO ENHANCE DOD’S ABILITY TO SANCTION CHINESE COMPANIESSenate Armed Services Committee draft loosens criteria for 1260H designation, codifies and expands research security policiesWed, 17 Jun 2026 14:25:26 -0700https://www.biocentury.com/article/659804/memo-details-h-eg-s-role-in-blocking-tzield-approvalhttps://www.biocentury.com/article/659804/memo-details-h-eg-s-role-in-blocking-tzield-approval?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMEMO DETAILS HØEG’S ROLE IN BLOCKING TZIELD APPROVAL Former Acting CDER director overruled career scientists, failed to document evidence supporting her decisionsWed, 17 Jun 2026 13:45:39 -0700https://www.biocentury.com/article/659792/democrats-drug-pricing-policies-build-on-trump-s-foundationhttps://www.biocentury.com/article/659792/democrats-drug-pricing-policies-build-on-trump-s-foundation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWDEMOCRATS’ DRUG PRICING POLICIES BUILD ON TRUMP’S FOUNDATIONShort-term tactical concessions by pharmas have created a platform for proposals to sharply reduce industry revenuesTue, 16 Jun 2026 17:33:58 -0700https://www.biocentury.com/article/659723/nanophoria-delivering-inhalable-biologics-to-the-hearthttps://www.biocentury.com/article/659723/nanophoria-delivering-inhalable-biologics-to-the-heart?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILENANOPHORIA: DELIVERING INHALABLE BIOLOGICS TO THE HEARTNanotechnology company aims to route peptides and nucleic acids to cardiac tissue by way of the lung, backed by Italy’s largest biotech series ATue, 16 Jun 2026 16:52:02 -0700https://www.biocentury.com/article/659754/tuning-nanoparticles-to-each-tumor-barrierhttps://www.biocentury.com/article/659754/tuning-nanoparticles-to-each-tumor-barrier?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONTUNING NANOPARTICLES TO EACH TUMOR BARRIERFour nanoparticle platforms for solid tumors, three from China, each designed to clear a specific barrier — new in BioCentury's Innovation DistilleryTue, 16 Jun 2026 15:21:20 -0700https://www.biocentury.com/article/659772/novartis-taps-orionis-for-second-molecular-glue-tie-up-deals-reporthttps://www.biocentury.com/article/659772/novartis-taps-orionis-for-second-molecular-glue-tie-up-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSNOVARTIS TAPS ORIONIS FOR SECOND MOLECULAR GLUE TIE-UP: DEALS REPORTPlus: Lilly/AlzeCure, Verge/Tenacia, and moreMon, 15 Jun 2026 16:56:57 -0700https://www.biocentury.com/article/659773/biotech-ipos-biosecure-act-cachexia-pipeline-a-biocentury-podcasthttps://www.biocentury.com/article/659773/biotech-ipos-biosecure-act-cachexia-pipeline-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEBIOTECH IPOS, BIOSECURE ACT, CACHEXIA PIPELINE — A BIOCENTURY PODCASTBiotech’s largest-ever IPO, leaders in the clinic for cachexia, and the latest from WashingtonMon, 15 Jun 2026 16:40:10 -0700https://www.biocentury.com/article/659777/tzield-approval-another-sign-makary-era-overhttps://www.biocentury.com/article/659777/tzield-approval-another-sign-makary-era-over?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONTZIELD APPROVAL ANOTHER SIGN MAKARY ERA OVERFDA’s approval of an sBLA for Tzield comes after a chaotic ride through Makary’s FDAMon, 15 Jun 2026 16:38:09 -0700